FDA Approves Pembrolizumab With Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
ReutersFeb 10, 2026 8:59 PM
Feb 10 (Reuters) - FDA:
FDA: APPROVES PEMBROLIZUMAB WITH PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, PRIMARY PERITONEAL CARCINOMA
FDA: ALSO APPROVED PD-L1 IHC 22C3 PHARMDX AS COMPANION DIAGNOSTIC DEVICE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.TradingKey
8 hours ago
Netflix After the Warner Deal: What Investors Should Know
TradingKey - For quite some time now, Netflix (NFLX) has been regarded as the premier subscription-based streaming service in the world, with a well-established history of growth through creative use of pricing power, developing hit programming, and relying very little on outside sources for licensiTradingKey
14 hours ago
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.TradingKey
Fri, Feb 6
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.TradingKey
Fri, Feb 6
